CRO market shift drives SynteractHCR growth as it moves to new facility

By Melissa Fassbender contact

- Last updated on GMT

(Image: SynteractHCR)
(Image: SynteractHCR)
SynteractHCR has moved to a new 38,000 square foot facility in Carlsbad, CA as it looks to fill the mid-market CRO void created by recent consolidation, says CEO.

Since it was founded in 1987, the contract research organization (CRO) has been headquartered in Carlsbad, CA – a “thrivingbiotech community,” ​which Steve Powell, SynteractHCR CEO, said has been good to the company.

We have longstanding customer relationships, and so it made sense to maintain the headquarters there, while also continuing to expand our East Coast presence in Morrisville, NC and grow across our European facilities​,” Powell told Outsourcing-Pharma.com.

Powell joined SynteractHCR in July​ of this year at which time he told us​ his goal was to ensure continued innovation. The company also added three senior executives​ to its management team in April.

The move the new facility also follows the company’s completed by the private equity firm Amulet Capital Partners, LP. Powell said the firm has been dedicated to growing the company’s business by improving service delivery.

We see an immediate opportunity to fill the mid-market CRO ‘void’ given recent consolidation in the industry​,” added Powell. “We remain true to developing customer relationships that are a match culturally while delivering per expectations, so this shift in the CRO market is one we see as a key growth driver​.”

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers